SANOFI US SERVICES INC. for SANOFI US SERVICES INC
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines; general issues related to Zika Outbreaks; general issues related to Tropical Disease PRV Program;general issues related to the value of prescription medicines and Japanese Biennial Pricing Review; issues related to S2512/H.R.4400 "Adding Zika Virus to the FDA Priority Review Voucher Program Act"; issues related to vaccine reimbursement; issues related to H.R. 3299 "Strengthening Public Health Emergency Response Act"; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; issues related to H.R. 5122 To prohibit further action on the proposed rule regarding testing of Medicare Part B prescription drug models; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| AMY L REDL | — |
| FRANCIS JOGUES RIENZO | — |
Animals ANI
Issues related to veterinary biologics National Environmental Policy Act (NEPA)exclusion; Issues related to animal compounding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
Taxation/Internal Revenue Code TAX
General issues related to corporate tax reform, including the deduction of interest; all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; issues related to Department of Treasury regulations on inversions.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| AMY L REDL | — |
Copyright/Patent/Trademark CPT
International intellectual property issues related to United Nations High Level Panel on Access, international intellectual property issues related to India, and international intellectual property provisions related to Canada.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JACOB ANDREW HARTSFIELD New | — |
Economics/Economic Development ECN
General issues related to the importance of foreign direct investment in the U.S.
Foreign entity interest: Sanofi SA, the foreign parent corporation of Sanofi US Services Inc. invests in its business in the U.S.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY L REDL | — |
Medicare/Medicaid MMM
General issues related to the Medicare Part D Program and government price setting; and provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; general issues related to Medicare Part B Reimbursement and Center for Medicaid and Medicare Innovation Part B rule
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
| AMY L REDL | — |
| FRANCIS JOGUES RIENZO New | — |
Pharmacy PHA
General issues related to the 340B Federal Drug Pricing Progranm
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARYANNE DOLBEARE DUNLAP | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.